ArticleJTO clinical and research reports2022

Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib.

Yuki Takeyasu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.